AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 24103486 — intervention group
Group type: COMPARATOR
Intervention: RASS (control group)
Number of subjects: 300
Study 22700888 — intervention group
Group type: EXPERIMENTAL
Intervention: Carvedilol (50 mg twice daily)
Number of subjects: 25
Study 22700888 — intervention group
Group type: COMPARATOR
Intervention: Control (baseline)
Number of subjects: 25
Study 20683945 — intervention group
Group type: EXPERIMENTAL
Intervention: peginterferon alfa-2a
Number of subjects: 107
Study 20683945 — intervention group
Group type: COMPARATOR
Intervention: peginterferon alfa-2a and ribavirin
Number of subjects: 107
Study 18036277 — intervention group
Group type: EXPERIMENTAL
Intervention: Coblation tonsillectomy
Number of subjects: 60
Study 18036277 — intervention group
Group type: COMPARATOR
Intervention: Monopolar electrocautery
Number of subjects: 60
Study 17013444 — intervention group
Group type: EXPERIMENTAL
Intervention: Peg‐IFN ‐2b 3.0 mcg/kg QW x 12 weeks followed by 1.5 mcg/kg QW x 36 weeks plus 800‐1200 mg ribavirin (Arm A)
Number of subjects: 188
Study 17013444 — intervention group
Group type: COMPARATOR
Intervention: Peg‐IFNalpha‐2b 1.5 mcg/kg QW x 48 weeks plus 800‐1200 mg ribavirin (Arm B)
Number of subjects: 188
Study 15297106 — intervention group
Group type: EXPERIMENTAL
Intervention: High fat oral supplement (70:25:5 fat:carbohydrate:protein)
Number of subjects: 16
Study 15297106 — intervention group
Group type: EXPERIMENTAL
Intervention: High carbohydrate oral supplement (25:70:5 fat:carbohydrate:protein)
Number of subjects: 16
Study 15297106 — intervention group
Group type: COMPARATOR
Intervention: Control group (no supplement)
Number of subjects: 16
Study 15297106 — intervention group
Group type: EXPERIMENTAL
Intervention: High fat and high carbohydrate supplements
Number of subjects: 16
Study 11296329 — intervention group
Group type: EXPERIMENTAL
Intervention: Dopexamine infusion at 2 microg/kg per minute (n = 12)
Number of subjects: 30
Study 11296329 — intervention group
Group type: COMPARATOR
Intervention: Placebo (0.9% saline) (n = 18)
Number of subjects: 30
Study 11296329 — intervention group
Group type: EXPERIMENTAL
Intervention: Dopexamine infusion
Number of subjects: 30
Study 9308523 — intervention group
Group type: EXPERIMENTAL
Intervention: Ligament reconstruction with tendon interposition (Group I)
Number of subjects: 20
Study 9308523 — intervention group
Group type: COMPARATOR
Intervention: Ligament reconstruction alone (Group II)
Number of subjects: 20
Study 9308523 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 20
Study 8115101 — intervention group
Group type: EXPERIMENTAL
Intervention: Peribulbar anesthesia with prilocaine 3% with felypressin and hyaluronidase
Number of subjects: 87
Study 8115101 — intervention group
Group type: COMPARATOR
Intervention: Retrobulbar anesthesia with prilocaine 3% with felypressin and hyaluronidase
Number of subjects: 87
Study 8115101 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (Peribulbar and Retrobulbar)
Number of subjects: 87
Study 3554493 — intervention group
Group type: EXPERIMENTAL
Intervention: Gastric bypass (n = 29)
Number of subjects: 57
Study 3554493 — intervention group
Group type: COMPARATOR
Intervention: Gastroplasty (n = 28)
Number of subjects: 57
Study 30538163 — intervention group
Group type: EXPERIMENTAL
Intervention: CPAP (Continuous Positive Airway Pressure) use averaged 2.9±2.3 hours per night, with 21% fully adherent (at least 4 hours use on 5 days per week).
Number of subjects: 149
Study 30538163 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group).
Number of subjects: 149
Study 28891908 — intervention group
Group type: EXPERIMENTAL
Intervention: Amantadine 100 mg twice daily
Number of subjects: 118
Study 28891908 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 118
Study 25749499 — intervention group
Group type: EXPERIMENTAL
Intervention: Graded activity (moderate intensity treadmill walking, brief education and strength exercises)
Number of subjects: 66
Study 25749499 — intervention group
Group type: COMPARATOR
Intervention: Physiotherapy (strengthening, stretching and motor control)
Number of subjects: 66
Study 23307542 — intervention group
Group type: EXPERIMENTAL
Intervention: Tacrolimus plus clotrimazole troche
Number of subjects: 6
Study 23307542 — intervention group
Group type: COMPARATOR
Intervention: Tacrolimus plus nystatin suspension
Number of subjects: 6
Study 20947382 — intervention group
Group type: EXPERIMENTAL
Intervention: Thoracic epidural analgesia with levobupivacaine for 6 postoperative days
Number of subjects: 50
Study 20947382 — intervention group
Group type: COMPARATOR
Intervention: Patient-controlled intravenous morphine starting on the 3rd postoperative day
Number of subjects: 50
Study 19858400 — intervention group
Group type: EXPERIMENTAL
Intervention: Lapatinib plus paclitaxel
Number of subjects: 579
Study 19858400 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus paclitaxel
Number of subjects: 579
Study 16913262 — intervention group
Group type: EXPERIMENTAL
Intervention: Olopatadine HCl nasal spray 0.6%
Number of subjects: 0
Study 16913262 — intervention group
Group type: EXPERIMENTAL
Intervention: Olopatadine HCl nasal spray 0.4%
Number of subjects: 0
Study 16913262 — intervention group
Group type: COMPARATOR
Intervention: Vehicle placebo
Number of subjects: 0
Study 15096077 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine 20 mg daily
Number of subjects: 0
Study 15096077 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 15096077 — intervention group
Group type: EXPERIMENTAL
Intervention: Enteric-coated fluoxetine 90 mg once weekly
Number of subjects: 0
Study 11237915 — intervention group
Group type: EXPERIMENTAL
Intervention: AAION
Number of subjects: 301
Study 11237915 — intervention group
Group type: COMPARATOR
Intervention: NAION
Number of subjects: 301
Study 9272343 — intervention group
Group type: EXPERIMENTAL
Intervention: Various pertussis vaccines
Number of subjects: 0
Study 9272343 — intervention group
Group type: COMPARATOR
Intervention: Laboratory-confirmed B. pertussis infection
Number of subjects: 0
Study 9272343 — intervention group
Group type: COMPARATOR
Intervention: Not-confirmed cases
Number of subjects: 0
Study 7705377 — intervention group
Group type: EXPERIMENTAL
Intervention: Maximal upright bicycle exercise
Number of subjects: 6
Study 3675257 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen
Number of subjects: 57
Study 3675257 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 57
Study 29253089 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Dose Influenza Vaccine (FluzoneHD, Sanofi)
Number of subjects: 172
Study 29253089 — intervention group
Group type: COMPARATOR
Intervention: Standard-Dose Influenza Vaccine (Fluviral, GSK)
Number of subjects: 172
Study 27599620 — intervention group
Group type: EXPERIMENTAL
Intervention: Feedback Game (FG)
Number of subjects: 50
Study 27599620 — intervention group
Group type: COMPARATOR
Intervention: No Feedback (NF)
Number of subjects: 50
Study 24459138 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoxaparin with HeprAN membrane
Number of subjects: 10
Study 24459138 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoxaparin with polysulphone (PS) membrane
Number of subjects: 10
Study 24459138 — intervention group
Group type: EXPERIMENTAL
Intervention: No enoxaparin with HeprAN membrane
Number of subjects: 10
Study 24459138 — intervention group
Group type: EXPERIMENTAL
Intervention: No enoxaparin with polysulphone (PS) membrane
Number of subjects: 10
Study 24459138 — intervention group
Group type: EXPERIMENTAL
Intervention: No enoxaparin with bubble trap
Number of subjects: 10
Study 24459138 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoxaparin with bubble trap
Number of subjects: 10
Study 24459138 — intervention group
Group type: EXPERIMENTAL
Intervention: Polysulphone membrane
Number of subjects: 10
Study 24459138 — intervention group
Group type: EXPERIMENTAL
Intervention: HeprAN membrane
Number of subjects: 10
Study 22918177 — intervention group
Group type: EXPERIMENTAL
Intervention: High-protein (HP) nutrition bar (280 kcal)
Number of subjects: 54
Study 22918177 — intervention group
Group type: EXPERIMENTAL
Intervention: High-carbohydrate (HC) nutrition bar (260 kcal)
Number of subjects: 54
Study 22918177 — intervention group
Group type: COMPARATOR
Intervention: Non-intervention day (control)
Number of subjects: 54
Study 20526620 — intervention group
Group type: EXPERIMENTAL
Intervention: Lightweight mesh fixed by fibrin glue
Number of subjects: 276
Study 20526620 — intervention group
Group type: COMPARATOR
Intervention: Clip fixation
Number of subjects: 276
Study 18770962 — intervention group
Group type: EXPERIMENTAL
Intervention: Abdominal surgical approach
Number of subjects: 0
Study 18770962 — intervention group
Group type: EXPERIMENTAL
Intervention: Transvaginal surgical approach
Number of subjects: 0
Study 18770962 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic and other transvaginal minimal access techniques
Number of subjects: 0
Study 18770962 — intervention group
Group type: EXPERIMENTAL
Intervention: Suspension of the vaginal apex to the uterosacral ligaments or sacrospinous ligaments
Number of subjects: 0
Study 15880023 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus 0.75-1.5 mg bid plus reduced-exposure cyclosporine (CsA) and prednisone
Number of subjects: 2
Study 15880023 — intervention group
Group type: COMPARATOR
Intervention: Reduced-exposure cyclosporine (CsA)
Number of subjects: 2
Study 12718222 — intervention group
Group type: EXPERIMENTAL
Intervention: Allicor (600 mg/day)
Number of subjects: 214
Study 12718222 — intervention group
Group type: EXPERIMENTAL
Intervention: Allicor (300 mg/day)
Number of subjects: 214
Study 12718222 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 214
Study 12718222 — intervention group
Group type: COMPARATOR
Intervention: Benzimidazole
Number of subjects: 214
Study 12718222 — intervention group
Group type: EXPERIMENTAL
Intervention: Allicor
Number of subjects: 214
Study 10469713 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg/day danazol for 6 months
Number of subjects: 28
Study 10469713 — intervention group
Group type: COMPARATOR
Intervention: No therapy (control)
Number of subjects: 28
Study 8737436 — intervention group
Group type: EXPERIMENTAL
Intervention: Interactional Group Discussion (IGD)
Number of subjects: 144
Study 8737436 — intervention group
Group type: COMPARATOR
Intervention: Control group (no IGD)
Number of subjects: 144
Study 1654756 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine with sodium bicarbonate
Number of subjects: 100
Study 1654756 — intervention group
Group type: COMPARATOR
Intervention: Lidocaine alone
Number of subjects: 100
Study 1654756 — intervention group
Group type: EXPERIMENTAL
Intervention: 16-gauge intravenous catheter
Number of subjects: 100
Study 1654756 — intervention group
Group type: COMPARATOR
Intervention: 20-gauge intravenous catheter
Number of subjects: 100
Study 6125184 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol 40 mg
Number of subjects: 10
Study 6125184 — intervention group
Group type: EXPERIMENTAL
Intervention: Pindolol 5 mg
Number of subjects: 10
Study 6125184 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol 50 mg
Number of subjects: 10
Study 6125184 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 30209607 — intervention group
Group type: EXPERIMENTAL
Intervention: Checklist group
Number of subjects: 80
Study 30209607 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 80
Study 29316176 — intervention group
Group type: EXPERIMENTAL
Intervention: Prandial insulin glulisine injection timing adjustment based on continuous glucose monitoring (arm B)
Number of subjects: 121
Study 29316176 — intervention group
Group type: COMPARATOR
Intervention: Pre-breakfast insulin glulisine injection (arm A)
Number of subjects: 121
Study 29316176 — intervention group
Group type: EXPERIMENTAL
Intervention: Prandial insulin glulisine dosage (arm B)
Number of subjects: 121
Study 29316176 — intervention group
Group type: COMPARATOR
Intervention: Prandial insulin glulisine dosage (arm A)
Number of subjects: 121
Study 29316176 — intervention group
Group type: EXPERIMENTAL
Intervention: Frequency of hypoglycaemic events (arm B)
Number of subjects: 121
Study 29316176 — intervention group
Group type: COMPARATOR
Intervention: Frequency of hypoglycaemic events (arm A)
Number of subjects: 121
Study 26968957 — intervention group
Group type: EXPERIMENTAL
Intervention: CODES management intervention combining management, diagnostic, and evaluation tools for child survival.
Number of subjects: 16
Study 26968957 — intervention group
Group type: EXPERIMENTAL
Intervention: CODES management intervention
Number of subjects: 16
Study 26968957 — intervention group
Group type: COMPARATOR
Intervention: Comparison districts (control)
Number of subjects: 16
Study 25296241 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrapleural tPA/DNase therapy
Number of subjects: 107
Study 23217889 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcutaneous electrical stimulation using interferential current (IFC) applied to the abdomen (12 sessions, 20 min, 3 times per week, <40 mA, carrier frequency 4 kHz, varying beat frequency 80-150 Hz)
Number of subjects: 8
Study 23217889 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcutaneous electrical stimulation using interferential current (IFC) applied to the abdomen
Number of subjects: 8
Study 20197759 — intervention group
Group type: EXPERIMENTAL
Intervention: Alosetron
Number of subjects: 998
Study 20197759 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 998
Study 18001430 — intervention group
Group type: EXPERIMENTAL
Intervention: Ass's milk (AM)
Number of subjects: 28
Study 18001430 — intervention group
Group type: COMPARATOR
Intervention: Goat's milk (GM)
Number of subjects: 28
Study 18001430 — intervention group
Group type: COMPARATOR
Intervention: Food challenge with GM
Number of subjects: 28
Study 18001430 — intervention group
Group type: EXPERIMENTAL
Intervention: Food challenge with AM
Number of subjects: 28
Study 15613075 — intervention group
Group type: EXPERIMENTAL
Intervention: Subgingival minocycline application plus scaling/root planing
Number of subjects: 15
Study 15613075 — intervention group
Group type: COMPARATOR
Intervention: Scaling/root planing alone
Number of subjects: 15
Study 12558470 — intervention group
Group type: EXPERIMENTAL
Intervention: Brinzolamide twice daily
Number of subjects: 0
Study 12558470 — intervention group
Group type: EXPERIMENTAL
Intervention: Brinzolamide three times daily
Number of subjects: 0
Study 12558470 — intervention group
Group type: EXPERIMENTAL
Intervention: Brinzolamide twice daily plus timolol
Number of subjects: 0
Study 12558470 — intervention group
Group type: EXPERIMENTAL
Intervention: Brinzolamide
Number of subjects: 0
Study 12558470 — intervention group
Group type: COMPARATOR
Intervention: Dorzolamide
Number of subjects: 0
Study 10346769 — intervention group
Group type: EXPERIMENTAL
Intervention: Promethazine (25 mg for adults and 0.5/kg for children)
Number of subjects: 101
Study 10346769 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 101
Study 8546884 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperhydrated subjects (0.1 g sodium chloride (NaCl)/kg body wt and 26 mL water/kg body wt)
Number of subjects: 30
Study 8546884 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypokinetic subjects (hypokinesia alone)
Number of subjects: 30
Study 8546884 — intervention group
Group type: COMPARATOR
Intervention: Control subjects (normal ambulatory conditions)
Number of subjects: 30
Study 2015394 — intervention group
Group type: EXPERIMENTAL
Intervention: 12.0 Gy total body irradiation
Number of subjects: 116
Study 2015394 — intervention group
Group type: COMPARATOR
Intervention: 15.75 Gy total body irradiation
Number of subjects: 116
Study 7280444 — intervention group
Group type: EXPERIMENTAL
Intervention: Target vaccine (containing serotypes 1, 3, 6, 7, 14, 18, 19, and 23)
Number of subjects: 179
Study 7280444 — intervention group
Group type: COMPARATOR
Intervention: Control vaccine (containing serotypes 2, 4, 5, 8, 9, 12, and 25)
Number of subjects: 179
Study 7280444 — intervention group
Group type: EXPERIMENTAL
Intervention: Infants with two or fewer episodes before immunization
Number of subjects: 179
Study 31365365 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary Fascial Closure (PFC)
Number of subjects: 129
Study 31365365 — intervention group
Group type: COMPARATOR
Intervention: Bridged Repair
Number of subjects: 129
Study 31365365 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (PFC and Bridged Repair)
Number of subjects: 129
Study 30642368 — intervention group
Group type: EXPERIMENTAL
Intervention: Wasted infants
Number of subjects: 1119
Study 30642368 — intervention group
Group type: EXPERIMENTAL
Intervention: Stunting
Number of subjects: 1119
Study 30642368 — intervention group
Group type: EXPERIMENTAL
Intervention: Underweight
Number of subjects: 1119
Study 30642368 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall prevalence of malnutrition
Number of subjects: 1119
Study 28137739 — intervention group
Group type: EXPERIMENTAL
Intervention: Etoposide 50 mg/m2 on days 1-5 and cisplatin 50 mg/m2 on days 1 and 8 every 4 weeks for two cycles (EP arm)
Number of subjects: 200
Study 28137739 — intervention group
Group type: COMPARATOR
Intervention: Paclitaxel 45 mg/m2 and carboplatin (AUC 2) on day 1 weekly (PC arm)
Number of subjects: 200
Study 28137739 — intervention group
Group type: EXPERIMENTAL
Intervention: Etoposide/cisplatin (EP arm)
Number of subjects: 200
Study 28137739 — intervention group
Group type: COMPARATOR
Intervention: Paclitaxel/carboplatin (PC arm)
Number of subjects: 200
Study 25584431 — intervention group
Group type: COMPARATOR
Intervention: Cylindrical polyvinyl chloride
Number of subjects: 604
Study 25584431 — intervention group
Group type: EXPERIMENTAL
Intervention: Cylindrical polyurethane
Number of subjects: 604
Study 25584431 — intervention group
Group type: EXPERIMENTAL
Intervention: Conical polyvinyl chloride
Number of subjects: 604
Study 25584431 — intervention group
Group type: EXPERIMENTAL
Intervention: Conical polyurethane
Number of subjects: 604
Study 25584431 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 604
Study 23954611 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban
Number of subjects: 1280
Study 23954611 — intervention group
Group type: COMPARATOR
Intervention: Warfarin
Number of subjects: 1280
Study 23227139 — intervention group
Group type: EXPERIMENTAL
Intervention: Active CPAP treatment
Number of subjects: 17
Study 23227139 — intervention group
Group type: COMPARATOR
Intervention: Sham CPAP treatment
Number of subjects: 17
Study 19577757 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT)
Number of subjects: 48
Study 19577757 — intervention group
Group type: COMPARATOR
Intervention: Waiting List Control (WLC)
Number of subjects: 48
Study 19577757 — intervention group
Group type: COMPARATOR
Intervention: Non-depressed controls
Number of subjects: 48
Study 17406837 — intervention group
Group type: EXPERIMENTAL
Intervention: Arginine (Arg; 20 g)
Number of subjects: 8
Study 17406837 — intervention group
Group type: COMPARATOR
Intervention: Amino acid mixture (AA)
Number of subjects: 8
Study 15063433 — intervention group
Group type: EXPERIMENTAL
Intervention: TEE-guided strategy
Number of subjects: 833
Study 15063433 — intervention group
Group type: COMPARATOR
Intervention: Conventional strategy
Number of subjects: 833
Study 17130272 — intervention group
Group type: EXPERIMENTAL
Intervention: Complete anemia correction
Number of subjects: 603
Study 17130272 — intervention group
Group type: COMPARATOR
Intervention: Partial anemia correction
Number of subjects: 603
Study 10232626 — intervention group
Group type: EXPERIMENTAL
Intervention: MCT diet
Number of subjects: 12
Study 10232626 — intervention group
Group type: COMPARATOR
Intervention: LCT diet
Number of subjects: 12
Study 8752805 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibutilide 0.005 mg/kg
Number of subjects: 200
Study 8752805 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibutilide 0.010 mg/kg
Number of subjects: 200
Study 8752805 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibutilide 0.015 mg/kg
Number of subjects: 200
Study 8752805 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibutilide 0.025 mg/kg
Number of subjects: 200
Study 8752805 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 200
Study 1677283 — intervention group
Group type: EXPERIMENTAL
Intervention: Closed postoperative peritoneal lavage
Number of subjects: 83
Study 1677283 — intervention group
Group type: COMPARATOR
Intervention: No closed postoperative peritoneal lavage (control)
Number of subjects: 83
Study 6419419 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium valproate (Valontin, Parke‐Davis)
Number of subjects: 12
Study 6419419 — intervention group
Group type: EXPERIMENTAL
Intervention: Valproic acid (Depakene capsules, Abbott)
Number of subjects: 12
Study 6419419 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium salt (Depakene syrup, Abbott)
Number of subjects: 12
Study 6419419 — intervention group
Group type: COMPARATOR
Intervention: Calcium valproate, Valproic acid, Sodium salt
Number of subjects: 12
Study 30892438 — intervention group
Group type: EXPERIMENTAL
Intervention: Capacitive resistive monopolar radiofrequency (RF=448 kHz)
Number of subjects: 24
Study 30892438 — intervention group
Group type: COMPARATOR
Intervention: Placebo radiofrequency
Number of subjects: 24
Study 29089455 — intervention group
Group type: EXPERIMENTAL
Intervention: Apixaban
Number of subjects: 1251
Study 29089455 — intervention group
Group type: COMPARATOR
Intervention: Warfarin
Number of subjects: 1251
Study 29089455 — intervention group
Group type: COMPARATOR
Intervention: None (control group)
Number of subjects: 1251
Study 26527775 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel plus trastuzumab and lapatinib (THL) for 16 weeks before surgery
Number of subjects: 305
Study 26527775 — intervention group
Group type: COMPARATOR
Intervention: Paclitaxel plus trastuzumab (TH) for 16 weeks before surgery
Number of subjects: 305
Study 26527775 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel plus lapatinib (TL)
Number of subjects: 305
Study 25246664 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled mannitol 400 mg twice a day for 52 weeks
Number of subjects: 461
Study 25246664 — intervention group
Group type: COMPARATOR
Intervention: Low-dose mannitol control
Number of subjects: 461
Study 21796421 — intervention group
Group type: EXPERIMENTAL
Intervention: 17 alpha-hydroxyprogesterone caproate (17‐OHPC) 250 mg intramuscularly
Number of subjects: 112
Study 21796421 — intervention group
Group type: COMPARATOR
Intervention: Placebo saline
Number of subjects: 112
Study 19960973 — intervention group
Group type: EXPERIMENTAL
Intervention: Wenhua Juanbi Recipe (WJR) in addition to methotrexate (MTX, 7.5 mg per week), sulfasalazine (0.5 g, tid), and meloxicam (Mobic, 7.5 mg, bid)
Number of subjects: 100